Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Raised by Fmr LLC

Fmr LLC boosted its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 26.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 92,498 shares of the company’s stock after acquiring an additional 19,622 shares during the period. Fmr LLC’s holdings in Voyager Therapeutics were worth $541,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of VYGR. Charles Schwab Investment Management Inc. raised its position in shares of Voyager Therapeutics by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock worth $804,000 after purchasing an additional 3,473 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Voyager Therapeutics by 19.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company’s stock worth $1,005,000 after buying an additional 28,333 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Voyager Therapeutics in the third quarter worth $74,000. Empowered Funds LLC increased its holdings in shares of Voyager Therapeutics by 5.4% in the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after acquiring an additional 2,278 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on VYGR shares. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Wedbush initiated coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 target price for the company. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Finally, Citigroup assumed coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $17.00.

Insider Transactions at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.53% of the stock is owned by insiders.

Voyager Therapeutics Trading Down 7.4 %

Shares of VYGR opened at $5.79 on Thursday. The business’s 50-day moving average price is $6.56 and its 200 day moving average price is $7.13. The stock has a market capitalization of $316.28 million, a P/E ratio of 8.16 and a beta of 0.90. Voyager Therapeutics, Inc. has a 1-year low of $5.19 and a 1-year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the prior year, the company earned ($0.59) earnings per share. On average, research analysts predict that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.